1 / 1

Hungry Hippos Engineering David Morgan, Kevin Richter, Neil Templeton

Hungry Hippos Engineering David Morgan, Kevin Richter, Neil Templeton. Components of System Stomach: Contains pH of 1 with a flow rate of 5 mL /s. Will be modeled by a BioFlow 150 Reactor. This will simulate the initial phase of drug adsorption.

lew
Télécharger la présentation

Hungry Hippos Engineering David Morgan, Kevin Richter, Neil Templeton

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hungry Hippos EngineeringDavid Morgan, Kevin Richter, Neil Templeton Components of System Stomach: Contains pH of 1 with a flow rate of 5 mL/s. Will be modeled by a BioFlow 150 Reactor. This will simulate the initial phase of drug adsorption. Small Intestines : Contains a pH of 4-5 and will simulate how much of the drug will be adsorbed into the blood stream. This will be represented by a perforated cylinder filter.Blood Stream: Will simulate where Captopril will inhibit the enzymes. This will be represented by Affinity Chromatography with the enzymes (ACE) immobilized in the column. Problem Statement To improve patient safety in oral pharmaceuticals a bioreactor will be developed to simulate drug adsorption from the small intestines into the blood stream. This system will improve understanding of drug delivery considering aspects such as adsorption, chemical reactions, enzyme kinetics. Development of a Bioreactor to Simulate Drug Adsorptionfrom the Small Intestines into the Blood StreamBiological Systems Engineering, Virginia Tech • Justification for Research • About 73.6 million American have high blood pressure. • In 2005, 57,356 deaths in the United States were caused by high blood pressure. • In 2002, Americans spent $12 billion dollars on high blood pressure medication • About 30-50% of total drug development costs go toward clinical trials. • This represents a monetary value of 50 – 300 million dollars, varying on the type of drug. • What is the price of safety? • Captopril • One of the most popular blood pressure medications on market today • Captopril works by competitive enzyme inhibition • 47% of current drugs on the market work by enzyme inhibition • Captopril inhibits Angiotensin Converting Enzyme (ACE) • ACE converts Angiotensin I into Angiotensin II • Compared to Angiotensin I, Angiotension II is 3x as powerful in blood vessel constriction • Therefore if ACE is restricted, blood pressure decreases • Future Work • If design can produce the in vivo measured rate constants already known, then the ability to predict a drug’s performance in the human body exists • Proper Dosage: Increased SAFETY with less side effects, less allergic reactions • NIH funds could make this a senior design next year and incorporates a biomedical focus into BSE Special thanks to Dr. Mike Zhang for his assistance and support

More Related